Ectopic Male Breast Cancer in Suprapubic Area That Relapsed with Hematogenous Metastasis.

Autor:	Byon JH; Department of Radiology, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea., An AR; Department of Pathology, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea., Shin JY; Department of Plastic and Reconstructive Surgery, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea., Choi EJ; Department of Radiology, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea. cejcej80@hanmail.net.
Jazyk:	angličtina
Zdroj:	Journal of breast cancer [J Breast Cancer] 2021 Jun; Vol. 24 (3), pp. 344-348. Date of Electronic Publication: 2021 Apr 12.
DOI:	10.4048/jbc.2021.24.e21
Abstrakt:	Tough ectopic male breast cancer is extremely rare, non-axillary ectopic male breast cancer is even rare. To date, the natural course and prognosis of this disease are not fully understood. Consequently, the appropriate treatment for this disease has not been established. We report on a patient with ectopic male breast cancer in the suprapubic area that relapsed with hematogenous metastasis 3 years after complete surgical resection and adjuvant treatment despite an early diagnosis. This unusual case highlights the need for new prognostic factors such as genomic profiling to predict whether ectopic male breast cancer is aggressive and to guide on the duration between follow-ups and the appropriate method for conducting them. Competing Interests: The authors declare that they have no competing interests. (© 2021 Korean Breast Cancer Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu